Literature DB >> 17803965

Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat.

Shalea Piteau1, Amy Olver, Su-Jin Kim, Kyle Winter, John Andrew Pospisilik, Francis Lynn, Susanne Manhart, Hans-Ulrich Demuth, Madeleine Speck, Raymond A Pederson, Christopher H S McIntosh.   

Abstract

In type 2 diabetes (T2DM) beta-cell responsiveness to glucose-dependent insulinotropic polypeptide (GIP) is reduced. In a model of T2DM, the VDF Zucker rat, GIP receptor mRNA and protein levels were shown to be down-regulated. Possible restoration of responsiveness to GIP in Zucker rats by reducing hyperglycemia has been examined. ZDF rats with extreme hyperglycemia demonstrated greater islet GIP receptor mRNA down-regulation (94.3+/-3.8%) than ZF rats (48.8+/-22.8%). GIP receptor mRNA levels in ZDF rats returned to 83.0+/-17.9% of lean following normalization of hyperglycemia by phlorizin treatment and pancreas perfusions demonstrated markedly improved GIP responsiveness. Treatment of VDF rats with a DP IV inhibitor (P32/98) resulted in improved glucose tolerance and restored sensitivity to GIP in isolated pancreata. These findings support the proposal that GIP receptor down-regulation in rodent T2DM is secondary to chronic hyperglycemia and that normalization of glycemia can restore GIP sensitivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17803965     DOI: 10.1016/j.bbrc.2007.08.115

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

1.  Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels.

Authors:  J Góralska; U Raźny; A Polus; J Stancel-Możwiłło; M Chojnacka; A Gruca; A Zdzienicka; A Dembińska-Kieć; B Kieć-Wilk; B Solnica; M Malczewska-Malec
Journal:  Int J Obes (Lond)       Date:  2017-12-13       Impact factor: 5.095

2.  Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.

Authors:  Tsuyoshi Yanagimachi; Yukihiro Fujita; Yasutaka Takeda; Jun Honjo; Kuralay K Atageldiyeva; Yumi Takiyama; Atsuko Abiko; Yuichi Makino; Timothy J Kieffer; Masakazu Haneda
Journal:  Diabetologia       Date:  2015-12-22       Impact factor: 10.122

3.  GIP contributes to islet trihormonal abnormalities in type 2 diabetes.

Authors:  Chee W Chia; Juliana O Odetunde; Wook Kim; Olga D Carlson; Luigi Ferrucci; Josephine M Egan
Journal:  J Clin Endocrinol Metab       Date:  2014-04-08       Impact factor: 5.958

4.  The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice.

Authors:  Chelsea R Hutch; Karen Roelofs; April Haller; Joyce Sorrell; Kyle Leix; David D D'Alessio; Robert Augustin; Randy J Seeley; Thomas Klein; Darleen A Sandoval
Journal:  Diabetologia       Date:  2019-08-14       Impact factor: 10.122

Review 5.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

6.  Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat.

Authors:  Katia Meirelles; Tamer Ahmed; Derek M Culnan; Christopher J Lynch; Charles H Lang; Robert N Cooney
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

7.  A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control.

Authors:  Scott B Widenmaier; Su-Jin Kim; Gary K Yang; Thomas De Los Reyes; Cuilan Nian; Ali Asadi; Yutaka Seino; Timothy J Kieffer; Yin Nam Kwok; Christopher H S McIntosh
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

8.  Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes.

Authors:  Dhananjay Gupta; Mina Peshavaria; Navjot Monga; Thomas L Jetton; Jack L Leahy
Journal:  Diabetes       Date:  2010-03-23       Impact factor: 9.461

9.  Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function.

Authors:  Luan Shu; Aleksey V Matveyenko; Julie Kerr-Conte; Jae-Hyoung Cho; Christopher H S McIntosh; Kathrin Maedler
Journal:  Hum Mol Genet       Date:  2009-04-21       Impact factor: 6.150

10.  Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Authors:  P V Højberg; T Vilsbøll; R Rabøl; F K Knop; M Bache; T Krarup; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2008-11-27       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.